Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
August 18, 2018
Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans
Vishal Shah, Chun Yang, Zancong Shen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 2, 2018
Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans
Caroline A Lee, Chun Yang, Vishal Shah, et al.
Modern Rheumatology
|
October 19, 2018
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
David Fitz-Patrick, Kent Roberson, Kiyoshi Niwa, et al.
RMD Open
|
April 17, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
Roy Fleischmann, Peter Winkle, Jesse Hall, et al.
RMD Open
|
March 14, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
Roy Fleischmann, Peter Winkle, Jeffrey N Miner, et al.
Journal of Clinical Pharmacology
|
May 8, 2018
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
Martin Kankam, Jesse Hall, Michael Gillen, et al.
ACS Chemical Neuroscience
|
December 26, 2022
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy
Winston T Chu, Jesse Hall, Anjela Gurrala, et al.
Clinical Drug Investigation
|
June 28, 2018
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
William B Smith, Jesse Hall, Jolene K Berg, et al.
Frontiers in Microbiology
|
February 10, 2016
Temperature-Dependent Gentamicin Resistance of Francisella tularensis is Mediated by Uptake Modulation
Kathleen Loughman, Jesse Hall, Samantha Knowlton, et al.
Critical Care Medicine
|
March 17, 2006
A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients
Shannon S Carson, John P Kress, Jo Ellen Rodgers, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
August 18, 2018
Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans
Vishal Shah, Chun Yang, Zancong Shen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 2, 2018
Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans
Caroline A Lee, Chun Yang, Vishal Shah, et al.
Modern Rheumatology
|
October 19, 2018
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
David Fitz-Patrick, Kent Roberson, Kiyoshi Niwa, et al.
RMD Open
|
April 17, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
Roy Fleischmann, Peter Winkle, Jesse Hall, et al.
RMD Open
|
March 14, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
Roy Fleischmann, Peter Winkle, Jeffrey N Miner, et al.
Journal of Clinical Pharmacology
|
May 8, 2018
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
Martin Kankam, Jesse Hall, Michael Gillen, et al.
ACS Chemical Neuroscience
|
December 26, 2022
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy
Winston T Chu, Jesse Hall, Anjela Gurrala, et al.
Clinical Drug Investigation
|
June 28, 2018
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
William B Smith, Jesse Hall, Jolene K Berg, et al.
Frontiers in Microbiology
|
February 10, 2016
Temperature-Dependent Gentamicin Resistance of Francisella tularensis is Mediated by Uptake Modulation
Kathleen Loughman, Jesse Hall, Samantha Knowlton, et al.
Critical Care Medicine
|
March 17, 2006
A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients
Shannon S Carson, John P Kress, Jo Ellen Rodgers, et al.
Page
of 4